Alkermes Says ADHD Drug Candidate Showed Meaningful Improvements in Phase 1b Study; Shares Up Pre-Bell

08:43 AM EDT, 09/21/2026 (MT Newswires) -- Alkermes (ALKS) said Monday its drug candidate ALKS 7290 showed clinically meaningful improvements from baseline on exploratory endpoints in a phase 1b study in patients with attention-deficit hyperactivity disorder or ADHD. The company said it measured improvements using the Adult ADHD Investigator Symptom Rating Scale and Clinical Global Impression-Severity Scale after 14 days of treatment. ALKS 7290 was generally well-tolerated at all doses tested in healthy volunteers and adults with ADHD, the company said. The study enrolled 50 adults with ADHD in a double-blind, placebo-controlled, parallel-group trial with two cohorts, it added. The company said it enrolled the first of an expected 312 participants in a phase-2 study this month. The trial will evaluate the safety and efficacy of once-daily and split doses of ALKS 7290 compared to placebo, with data expected next year. Shares of the company were up over 7% in Monday's premarket activity. Price: 46.50, Change: +3.11, Percent Change: +7.17